Author: Theam Soon Lim
Publisher: Springer
ISBN: 9783030101534
Category : Medical
Languages : en
Pages : 0
Book Description
There are many principles and applications of recombinant antibodies for infectious diseases. The preferred technology associated to recombinant antibody generation is mainly phage display. The adaptation of antibodies for infectious diseases is an area lacking information as most literature is focused on oncology or autoimmunity. This project highlights the power and potential of antibody phage display for infectious diseases. In addition to that, supplementary information regarding technologies associated to antibody generation and engineering in the context of infectious disease will also help to provide greater insight to the potential of recombinant antibodies for infectious diseases.
Recombinant Antibodies for Infectious Diseases
Author: Theam Soon Lim
Publisher: Springer
ISBN: 9783030101534
Category : Medical
Languages : en
Pages : 0
Book Description
There are many principles and applications of recombinant antibodies for infectious diseases. The preferred technology associated to recombinant antibody generation is mainly phage display. The adaptation of antibodies for infectious diseases is an area lacking information as most literature is focused on oncology or autoimmunity. This project highlights the power and potential of antibody phage display for infectious diseases. In addition to that, supplementary information regarding technologies associated to antibody generation and engineering in the context of infectious disease will also help to provide greater insight to the potential of recombinant antibodies for infectious diseases.
Publisher: Springer
ISBN: 9783030101534
Category : Medical
Languages : en
Pages : 0
Book Description
There are many principles and applications of recombinant antibodies for infectious diseases. The preferred technology associated to recombinant antibody generation is mainly phage display. The adaptation of antibodies for infectious diseases is an area lacking information as most literature is focused on oncology or autoimmunity. This project highlights the power and potential of antibody phage display for infectious diseases. In addition to that, supplementary information regarding technologies associated to antibody generation and engineering in the context of infectious disease will also help to provide greater insight to the potential of recombinant antibodies for infectious diseases.
Recombinant Antibodies for Immunotherapy
Author: Melvyn Little
Publisher: Cambridge University Press
ISBN: 1139481096
Category : Medical
Languages : en
Pages : 445
Book Description
Recombinant Antibodies for Immunotherapy provides a comprehensive overview of the field of monoclonal antibodies (mAbs), a market that has grown tremendously in recent years. Twenty-five articles by experienced and innovative authors cover the isolation of specific human mAbs, humanization, immunogenicity, technologies for improving efficacy, 'arming' mAbs, novel alternative Ab constructs, increasing half-lives, alternative concepts employing non-immunoglobulin scaffolds, novel therapeutic approaches, a market analysis of therapeutic mAbs, and future developments in the field. The concepts and technologies are illustrated by examples of recombinant antibodies being used in the clinic or in development. This book will appeal to both newcomers and experienced scientists in the field, biology and biotechnology students, research and development departments in the pharmaceutical industry, medical researchers, clinicians, and biotechnology investors.
Publisher: Cambridge University Press
ISBN: 1139481096
Category : Medical
Languages : en
Pages : 445
Book Description
Recombinant Antibodies for Immunotherapy provides a comprehensive overview of the field of monoclonal antibodies (mAbs), a market that has grown tremendously in recent years. Twenty-five articles by experienced and innovative authors cover the isolation of specific human mAbs, humanization, immunogenicity, technologies for improving efficacy, 'arming' mAbs, novel alternative Ab constructs, increasing half-lives, alternative concepts employing non-immunoglobulin scaffolds, novel therapeutic approaches, a market analysis of therapeutic mAbs, and future developments in the field. The concepts and technologies are illustrated by examples of recombinant antibodies being used in the clinic or in development. This book will appeal to both newcomers and experienced scientists in the field, biology and biotechnology students, research and development departments in the pharmaceutical industry, medical researchers, clinicians, and biotechnology investors.
Recombinant Antibodies for Infectious Diseases
Author: Theam Soon Lim
Publisher: Springer
ISBN: 3319720775
Category : Medical
Languages : en
Pages : 307
Book Description
There are many principles and applications of recombinant antibodies for infectious diseases. The preferred technology associated to recombinant antibody generation is mainly phage display. The adaptation of antibodies for infectious diseases is an area lacking information as most literature is focused on oncology or autoimmunity. This project highlights the power and potential of antibody phage display for infectious diseases. In addition to that, supplementary information regarding technologies associated to antibody generation and engineering in the context of infectious disease will also help to provide greater insight to the potential of recombinant antibodies for infectious diseases.
Publisher: Springer
ISBN: 3319720775
Category : Medical
Languages : en
Pages : 307
Book Description
There are many principles and applications of recombinant antibodies for infectious diseases. The preferred technology associated to recombinant antibody generation is mainly phage display. The adaptation of antibodies for infectious diseases is an area lacking information as most literature is focused on oncology or autoimmunity. This project highlights the power and potential of antibody phage display for infectious diseases. In addition to that, supplementary information regarding technologies associated to antibody generation and engineering in the context of infectious disease will also help to provide greater insight to the potential of recombinant antibodies for infectious diseases.
Monoclonal Antibody Production
Author: National Research Council
Publisher: National Academies Press
ISBN: 0309173051
Category : Medical
Languages : en
Pages : 74
Book Description
The American Anti-Vivisection Society (AAVS) petitioned the National Institutes of Health (NIH) on April 23, 1997, to prohibit the use of animals in the production of mAb. On September 18, 1997, NIH declined to prohibit the use of mice in mAb production, stating that "the ascites method of mAb production is scientifically appropriate for some research projects and cannot be replaced." On March 26, 1998, AAVS submitted a second petition, stating that "NIH failed to provide valid scientific reasons for not supporting a proposed ban." The office of the NIH director asked the National Research Council to conduct a study of methods of producing mAb. In response to that request, the Research Council appointed the Committee on Methods of Producing Monoclonal Antibodies, to act on behalf of the Institute for Laboratory Animal Research of the Commission on Life Sciences, to conduct the study. The 11 expert members of the committee had extensive experience in biomedical research, laboratory animal medicine, animal welfare, pain research, and patient advocacy (Appendix B). The committee was asked to determine whether there was a scientific necessity for the mouse ascites method; if so, whether the method caused pain or distress; and, if so, what could be done to minimize the pain or distress. The committee was also asked to comment on available in vitro methods; to suggest what acceptable scientific rationale, if any, there was for using the mouse ascites method; and to identify regulatory requirements for the continued use of the mouse ascites method. The committee held an open data-gathering meeting during which its members summarized data bearing on those questions. A 1-day workshop (Appendix A) was attended by 34 participants, 14 of whom made formal presentations. A second meeting was held to finalize the report. The present report was written on the basis of information in the literature and information presented at the meeting and the workshop.
Publisher: National Academies Press
ISBN: 0309173051
Category : Medical
Languages : en
Pages : 74
Book Description
The American Anti-Vivisection Society (AAVS) petitioned the National Institutes of Health (NIH) on April 23, 1997, to prohibit the use of animals in the production of mAb. On September 18, 1997, NIH declined to prohibit the use of mice in mAb production, stating that "the ascites method of mAb production is scientifically appropriate for some research projects and cannot be replaced." On March 26, 1998, AAVS submitted a second petition, stating that "NIH failed to provide valid scientific reasons for not supporting a proposed ban." The office of the NIH director asked the National Research Council to conduct a study of methods of producing mAb. In response to that request, the Research Council appointed the Committee on Methods of Producing Monoclonal Antibodies, to act on behalf of the Institute for Laboratory Animal Research of the Commission on Life Sciences, to conduct the study. The 11 expert members of the committee had extensive experience in biomedical research, laboratory animal medicine, animal welfare, pain research, and patient advocacy (Appendix B). The committee was asked to determine whether there was a scientific necessity for the mouse ascites method; if so, whether the method caused pain or distress; and, if so, what could be done to minimize the pain or distress. The committee was also asked to comment on available in vitro methods; to suggest what acceptable scientific rationale, if any, there was for using the mouse ascites method; and to identify regulatory requirements for the continued use of the mouse ascites method. The committee held an open data-gathering meeting during which its members summarized data bearing on those questions. A 1-day workshop (Appendix A) was attended by 34 participants, 14 of whom made formal presentations. A second meeting was held to finalize the report. The present report was written on the basis of information in the literature and information presented at the meeting and the workshop.
Biosimilars of Monoclonal Antibodies
Author: Cheng Liu
Publisher: John Wiley & Sons
ISBN: 1118940628
Category : Medical
Languages : en
Pages : 723
Book Description
Addressing a significant need by describing the science and process involved to develop biosimilars of monoclonal antibody (mAb) drugs, this book covers all aspects of biosimilar development: preclinical, clinical, regulatory, manufacturing. • Guides readers through the complex landscape involved with developing biosimilar versions of monoclonal antibody (mAb) drugs • Features flow charts, tables, and figures that clearly illustrate processes and makes the book comprehensible and accessible • Includes a review of FDA-approved mAb drugs as a quick reference to facts and useful information • Examines new technologies and strategies for improving biosimilar mAbs
Publisher: John Wiley & Sons
ISBN: 1118940628
Category : Medical
Languages : en
Pages : 723
Book Description
Addressing a significant need by describing the science and process involved to develop biosimilars of monoclonal antibody (mAb) drugs, this book covers all aspects of biosimilar development: preclinical, clinical, regulatory, manufacturing. • Guides readers through the complex landscape involved with developing biosimilar versions of monoclonal antibody (mAb) drugs • Features flow charts, tables, and figures that clearly illustrate processes and makes the book comprehensible and accessible • Includes a review of FDA-approved mAb drugs as a quick reference to facts and useful information • Examines new technologies and strategies for improving biosimilar mAbs
Plant-derived Pharmaceuticals
Author: Kathleen L Hefferon
Publisher: CABI
ISBN: 1780643438
Category : Science
Languages : en
Pages : 182
Book Description
Describing recent developments in the engineering and generation of plants as production platforms for biopharmaceuticals, this book includes both vaccines and monoclonal antibodies. It has a particular emphasis on targeting diseases which predominate in less developed countries, encompassing the current state of technologies and describing expression systems and applications. This book also includes a variety of vaccine case studies, protecting against pervasive infectious diseases such as rabies, influenza and HIV.
Publisher: CABI
ISBN: 1780643438
Category : Science
Languages : en
Pages : 182
Book Description
Describing recent developments in the engineering and generation of plants as production platforms for biopharmaceuticals, this book includes both vaccines and monoclonal antibodies. It has a particular emphasis on targeting diseases which predominate in less developed countries, encompassing the current state of technologies and describing expression systems and applications. This book also includes a variety of vaccine case studies, protecting against pervasive infectious diseases such as rabies, influenza and HIV.
Handbook of Therapeutic Antibodies
Author: Stefan Dübel
Publisher: John Wiley & Sons
ISBN: 3527329374
Category : Science
Languages : en
Pages : 2538
Book Description
Dieses Nachschlagewerk zu therapeutischen Antikörpern sucht auch in der komplett überarbeiteten 2. Auflage seinesgleichen und bietet 30 % neue Inhalte zu Entwicklung, Herstellung und therapeutischen Anwendungen dieser Biomoleküle.
Publisher: John Wiley & Sons
ISBN: 3527329374
Category : Science
Languages : en
Pages : 2538
Book Description
Dieses Nachschlagewerk zu therapeutischen Antikörpern sucht auch in der komplett überarbeiteten 2. Auflage seinesgleichen und bietet 30 % neue Inhalte zu Entwicklung, Herstellung und therapeutischen Anwendungen dieser Biomoleküle.
Protein Therapeutics, 2 Volume Set
Author: Tristan Vaughan
Publisher: John Wiley & Sons
ISBN: 3527340866
Category : Medical
Languages : en
Pages : 762
Book Description
Branchenführende Big-Pharma-Unternehmen und erstklassige Forscher präsentieren grundlegende Konzepte und Herausforderungen bei proteinbasierten Pharmazeutika. Beinhaltet auch eine Einführung in die aus Sicht der Arzneimittelentwicklung fünf wesentlichen Anwendungsbereiche.
Publisher: John Wiley & Sons
ISBN: 3527340866
Category : Medical
Languages : en
Pages : 762
Book Description
Branchenführende Big-Pharma-Unternehmen und erstklassige Forscher präsentieren grundlegende Konzepte und Herausforderungen bei proteinbasierten Pharmazeutika. Beinhaltet auch eine Einführung in die aus Sicht der Arzneimittelentwicklung fünf wesentlichen Anwendungsbereiche.
Bispecific Antibodies
Author: Roland E. Kontermann
Publisher: Springer Science & Business Media
ISBN: 3642209106
Category : Medical
Languages : en
Pages : 381
Book Description
The concept of using bispecific antibodies for cancer therapy by retargeting immune effector cells was developed several years ago. Initial clinical studies were rather disappointing mainly due to low efficacy, severe side effects and the immunogenicity of the bispecific antibodies. The progress in antibody engineering finally led to the generation of new classes of bispecific antibodies lacking these obstacles. In addition, new applications were established, such as pre-targeting strategies in radioimmunotherapy and dual targeting approaches in order to improve binding, selectivity and efficacy. In this book, the different ways of generating bispecific antibodies are described, with emphasis on recombinant formats. The various applications of bispecific antibodies, e.g. in cellular cancer immunotherapy, radioimmunotherapy and pretargeting strategies are covered, and emerging applications such as dual targeting strategies, which involve the simultaneous inhibition of two targets, are addressed.
Publisher: Springer Science & Business Media
ISBN: 3642209106
Category : Medical
Languages : en
Pages : 381
Book Description
The concept of using bispecific antibodies for cancer therapy by retargeting immune effector cells was developed several years ago. Initial clinical studies were rather disappointing mainly due to low efficacy, severe side effects and the immunogenicity of the bispecific antibodies. The progress in antibody engineering finally led to the generation of new classes of bispecific antibodies lacking these obstacles. In addition, new applications were established, such as pre-targeting strategies in radioimmunotherapy and dual targeting approaches in order to improve binding, selectivity and efficacy. In this book, the different ways of generating bispecific antibodies are described, with emphasis on recombinant formats. The various applications of bispecific antibodies, e.g. in cellular cancer immunotherapy, radioimmunotherapy and pretargeting strategies are covered, and emerging applications such as dual targeting strategies, which involve the simultaneous inhibition of two targets, are addressed.
The Immunoassay Handbook
Author: David Wild
Publisher: Newnes
ISBN: 0080970389
Category : Science
Languages : en
Pages : 1037
Book Description
The fourth edition of The Immunoassay Handbook provides an excellent, thoroughly updated guide to the science, technology and applications of ELISA and other immunoassays, including a wealth of practical advice. It encompasses a wide range of methods and gives an insight into the latest developments and applications in clinical and veterinary practice and in pharmaceutical and life science research. Highly illustrated and clearly written, this award-winning reference work provides an excellent guide to this fast-growing field. Revised and extensively updated, with over 30% new material and 77 chapters, it reveals the underlying common principles and simplifies an abundance of innovation. The Immunoassay Handbook reviews a wide range of topics, now including lateral flow, microsphere multiplex assays, immunohistochemistry, practical ELISA development, assay interferences, pharmaceutical applications, qualitative immunoassays, antibody detection and lab-on-a-chip. This handbook is a must-read for all who use immunoassay as a tool, including clinicians, clinical and veterinary chemists, biochemists, food technologists, environmental scientists, and students and researchers in medicine, immunology and proteomics. It is an essential reference for the immunoassay industry. Provides an excellent revised guide to this commercially highly successful technology in diagnostics and research, from consumer home pregnancy kits to AIDS testing.www.immunoassayhandbook.com is a great resource that we put a lot of effort into. The content is designed to encourage purchases of single chapters or the entire book. David Wild is a healthcare industry veteran, with experience in biotechnology, pharmaceuticals, medical devices and immunodiagnostics, which remains his passion. He worked for Amersham, Eastman-Kodak, Johnson & Johnson, and Bristol-Myers Squibb, and consulted for diagnostics and biotechnology companies. He led research and development programs, design and construction of chemical and biotechnology plants, and integration of acquired companies. Director-level positions included Research and Development, Design Engineering, Operations and Strategy, for billion dollar businesses. He retired from full-time work in 2012 to focus on his role as Editor of The Immunoassay Handbook, and advises on product development, manufacturing and marketing. - Provides a unique mix of theory, practical advice and applications, with numerous examples - Offers explanations of technologies under development and practical insider tips that are sometimes omitted from scientific papers - Includes a comprehensive troubleshooting guide, useful for solving problems and improving assay performancee - Provides valuable chapter updates, now available on www.immunoassayhandbook.com
Publisher: Newnes
ISBN: 0080970389
Category : Science
Languages : en
Pages : 1037
Book Description
The fourth edition of The Immunoassay Handbook provides an excellent, thoroughly updated guide to the science, technology and applications of ELISA and other immunoassays, including a wealth of practical advice. It encompasses a wide range of methods and gives an insight into the latest developments and applications in clinical and veterinary practice and in pharmaceutical and life science research. Highly illustrated and clearly written, this award-winning reference work provides an excellent guide to this fast-growing field. Revised and extensively updated, with over 30% new material and 77 chapters, it reveals the underlying common principles and simplifies an abundance of innovation. The Immunoassay Handbook reviews a wide range of topics, now including lateral flow, microsphere multiplex assays, immunohistochemistry, practical ELISA development, assay interferences, pharmaceutical applications, qualitative immunoassays, antibody detection and lab-on-a-chip. This handbook is a must-read for all who use immunoassay as a tool, including clinicians, clinical and veterinary chemists, biochemists, food technologists, environmental scientists, and students and researchers in medicine, immunology and proteomics. It is an essential reference for the immunoassay industry. Provides an excellent revised guide to this commercially highly successful technology in diagnostics and research, from consumer home pregnancy kits to AIDS testing.www.immunoassayhandbook.com is a great resource that we put a lot of effort into. The content is designed to encourage purchases of single chapters or the entire book. David Wild is a healthcare industry veteran, with experience in biotechnology, pharmaceuticals, medical devices and immunodiagnostics, which remains his passion. He worked for Amersham, Eastman-Kodak, Johnson & Johnson, and Bristol-Myers Squibb, and consulted for diagnostics and biotechnology companies. He led research and development programs, design and construction of chemical and biotechnology plants, and integration of acquired companies. Director-level positions included Research and Development, Design Engineering, Operations and Strategy, for billion dollar businesses. He retired from full-time work in 2012 to focus on his role as Editor of The Immunoassay Handbook, and advises on product development, manufacturing and marketing. - Provides a unique mix of theory, practical advice and applications, with numerous examples - Offers explanations of technologies under development and practical insider tips that are sometimes omitted from scientific papers - Includes a comprehensive troubleshooting guide, useful for solving problems and improving assay performancee - Provides valuable chapter updates, now available on www.immunoassayhandbook.com